Website profile

@Oncodaily

OncoDaily is a specialized oncology news and information platform that provides daily updates on oncology research, treatments, clinical trials, and advancements in cancer care. It serves healthcare professionals, researchers, and patients by delivering timely and accurate insights into the latest developments in the f

  • 824articles · 30d
  • 2+ hour agolatest article
  • Aug 14, 2026earliest in window
  • 10%with images · 19 videos
  • 188avg words
articles per day
Categories
  • Health & Wellness 796
  • Medical 762
  • Health 753
  • Education & Jobs 40
  • Human Interest 25
  • Science & Technology 19
  • Education 15
  • Business & Industrial 6

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

Google News
oncodaily.com > voices > cosimo-commisso-pancreatic-cancer-585561

Cosimo Commisso: Pancreatic Cancer Builds Immune Safe Zones to Evade Treatment

3+ hour, 57+ min ago   (197+ words) / Alessia Baccarini, Alexander Tepper, Bhavya Singh, Brian D. Brownsvg, cancer,, Alessia Baccarini, Alexander Tepper, Bhavya Singh, Brian D. Brownsvg, cancer, Chiara Falcomatà, Cosimo Commisso, Divya Chhamalwan, Gurkan Mollaoglu, Hunter T. Potak, Icahn School of Medicine at Mount Sinai, Matthew D. Park, Maxime…...

Oncodaily - Oncology News
oncodaily.com > grant > gilead-research-scholars-program-585240

Gilead Research Scholars Program in Solid Tumors 2026 - Oncology News, Insights, Stories by OncoDaily

10+ hour, 12+ min ago   (149+ words) Gilead Research Scholars Program in Solid Tumors 2026 Oncodaily Gilead Research Scholars Program in Solid Tumors 2026 The Gilead Research Scholars Program in Solid Tumors 2026 supports early-career investigators conducting independent basic or clinical research addressing unmet needs in breast, endometrial, ovarian, or…...

Oncodaily - Oncology News
oncodaily.com > science > myeloma-paper-of-the-day-585368

Myeloma Paper of the Day, September 13th, Suggested by Robert Orlowski - OncoDaily

6+ hour, 57+ min ago   (253+ words) Myeloma Paper of the Day, September 13th, Suggested by Robert Orlowski / Anastasia Zekeridou, Andre de Menezes Silva Corraes, Blood Cancer Journal, cancer,, Anastasia Zekeridou, Andre de Menezes Silva Corraes, Blood Cancer Journal, cancer, Christoph Schaefers, Darin Carabenciov, Erin Wiedmeier-Nutor, Joselle Cook,…...

Oncodaily - Oncology News
oncodaily.com > voices > agenus-585146

September Stakeholder Webcast on ROBBIN Phase 3 and Neoadjuvant Immunotherapy - Agenus - OncoDaily

6+ hour, 40+ min ago   (100+ words) OncoDaily is a specialized news and information platform that provides daily updates on oncology research, treatments, clinical trials, and advancements in cancer care. It serves healthcare professionals, researchers, and patients by delivering timely and accurate insights into the latest developments…...

Google News
oncodaily.com > grant > sarcoma-foundation-585072

Sarcoma Foundation of America Research Grants 2027 - Oncology News, Insights, Stories by OncoDaily

23+ hour, 18+ min ago   (194+ words) OncoDaily is a specialized news and information platform that provides daily updates on oncology research, treatments, clinical trials, and advancements in cancer care. It serves healthcare professionals, researchers, and patients by delivering timely and accurate insights into the latest developments…...

Oncodaily - Oncology News
oncodaily.com > voices > liang-cheng-582963

Liang Cheng: Can Molecular Classification Improve Outcomes in Prostatic Neuroendocrine Tumors? - OncoDaily

3+ day, 11+ hour ago   (208+ words) Liang Cheng, Director of Anatomic and Molecular Pathology at Brown Pathology and Laboratory Medicine, shared on LinkedIn: “In case you missed my earlier post, here’s the companion (twin!) comprehensive review on prostatic neuroendocrine tumors, published in Endocrine Pathology, written by…...

Google News
oncodaily.com > voices > giuseppe-banna-583049

Giuseppe Banna?? Exploring Immunotherapy as a Double-Edged Sword

5+ day, 2+ hour ago   (50+ words) Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared on X: “Spot on talk by Xue-Yan Jiang immunotherapy as a double-edged sword. While IO revolutionises cancer care, managing irAEs remains key. We needed predictors, early clinical markers and…...

Oncodaily - Oncology News
oncodaily.com > voices > the-babak-lab-582830

Merck and Moderna Announce Positive Phase 3 Results for Intismeran Autogene Plus Pembrolizumab in High-Risk Melanoma - The Babak Lab - OncoDaily

5+ day, 6+ hour ago   (88+ words) The Babak Lab shared on LinkedIn: “Merck and Moderna have announced positive top-line results from the Phase 3 INTerpath-001 trial of intismeran autogene (V940) + pembrolizumab in patients with resected high-risk melanoma. INTerpath-001 is the first positive Phase 3 trial of an individualized neoantigen…...

Google News
oncodaily.com > science > lung-cancer-europe-2

Tumor Immune Changes Predict Immunotherapy Response - Lung Cancer Europe

6+ day, 3+ hour ago   (126+ words) Lung Cancer Europe shared on LinkedIn: “Changes after immunotherapy starts may be more informative than a sample taken before treatment begins. New research published in Cancer Cell looked at how the tumour immune environment changes during checkpoint inhibitor treatment. The…...

Google News
oncodaily.com > voices > eleonora-dondossola-kidney-cancer-582137

Eleonora Dondossola: New R01 Funding Advances Research in Metastatic Kidney Cancer

6+ day, 7+ hour ago   (156+ words) Eleonora Dondossola, Assistant Professor in the Department of Genitourinary Medical Oncology – Research, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, shared on LinkedIn: “Big celebrations for my first R01! This funding will allow us to investigate…...